Does NIRAPARIB Cause Tumour marker increased? 356 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 356 reports of Tumour marker increased have been filed in association with NIRAPARIB (ZEJULA). This represents 1.7% of all adverse event reports for NIRAPARIB.
356
Reports of Tumour marker increased with NIRAPARIB
1.7%
of all NIRAPARIB reports
9
Deaths
74
Hospitalizations
How Dangerous Is Tumour marker increased From NIRAPARIB?
Of the 356 reports, 9 (2.5%) resulted in death, 74 (20.8%) required hospitalization, and 9 (2.5%) were considered life-threatening.
Is Tumour marker increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NIRAPARIB. However, 356 reports have been filed with the FAERS database.
What Other Side Effects Does NIRAPARIB Cause?
Nausea (5,794)
Fatigue (5,240)
Constipation (4,128)
Platelet count decreased (4,102)
Insomnia (2,861)
Blood pressure increased (2,464)
Headache (2,383)
Off label use (2,213)
Vomiting (2,029)
Carbohydrate antigen 125 increased (1,868)
What Other Drugs Cause Tumour marker increased?
PALBOCICLIB (817)
FULVESTRANT (408)
LETROZOLE (343)
RIBOCICLIB (317)
RUCAPARIB CAMSYLATE (257)
CAPECITABINE (228)
EVEROLIMUS (228)
ELACESTRANT (222)
OLAPARIB (171)
ANASTROZOLE (142)
Which NIRAPARIB Alternatives Have Lower Tumour marker increased Risk?
NIRAPARIB vs NIRMATRELVIR\RITONAVIR
NIRAPARIB vs NIROGACESTAT
NIRAPARIB vs NIROGACESTAT HYDROBROMIDE
NIRAPARIB vs NIRSEVIMAB
NIRAPARIB vs NIRSEVIMAB-ALIP